Literature DB >> 19888793

Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.

Sripen Tantivess1, Yot Teerawattananon, Anne Mills.   

Abstract

Capacity is limited in the developing world to conduct cost-effectiveness analysis (CEA) of health interventions. In Thailand, there have been concerted efforts to promote evidence-based policy making, including the introduction of economic appraisals within health technology assessment (HTA). This paper reviews the experience of this lower middle-income country, with an emphasis on the creation of the Health Intervention and Technology Assessment Program (HITAP), including its mission, management structures and activities. Over the past 3 decades, several HTA programmes were implemented in Thailand but not sustained or developed further into a national institute. As a response to increasing demands for HTA evidence including CEA information, the HITAP was created in 2007 as an affiliate unit of a semi-autonomous research arm of the Ministry of Public Health. An advantage of this HTA programme over previous initiatives was that it was hosted by a research institute with long-term experience in conducting health systems and policy research and capacity building of its research staff, and excellent research and policy networks. To deal with existing impediments to conducting health economics research, the main strategies of the HITAP were carefully devised to include not only capacity strengthening of its researchers and administrative staff, but also the development of essential elements for the country's health economic evaluation methodology. These included, for example, methodological guidelines, standard protocols and benchmarks for resource allocation, many of which have been adopted by national policy-making bodies including the three major public health insurance plans. Networks and collaborations with domestic and foreign institutes have been sought as a means of resource mobilization and exchange. Although the HITAP is well financed by a number of government agencies and international organizations, the programme is vulnerable to shortages of qualified research staff, as most staff work on a part-time or temporary basis. To enhance the utilization of its research findings by policy makers, practitioners and consumers, the HITAP has adopted the principles of technical excellence, policy relevance, transparency, effective communication and participation of key stakeholders. These principles have been translated into good practice at every step of HTA management. In 2007 and 2008, the HITAP carried out assessments of a wide range of health products, medical procedures and public health initiatives. Although CEA and other economic evaluation approaches were employed in these studies, the tools and underlying efficiency goal were considered inadequate to provide complete information for prioritization. As suggested by official stakeholders, some of the projects investigated broader issues of management, feasibility, performance and socio-political implications of interventions. As yet, it is unclear what role HITAP research and associated recommendations have played in policy decisions. It is hoped that the lessons drawn on the creation of the HITAP and its experience during the first 2 years, as well as information on its main strategies and management structures, may be helpful for other resource-constrained countries when considering how best to strengthen their capacity to conduct economic appraisals of health technologies and interventions.

Entities:  

Mesh:

Year:  2009        PMID: 19888793     DOI: 10.2165/11314710-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  18 in total

1.  Using evidence to inform health policy: case study.

Authors:  S Macintyre; I Chalmers; R Horton; R Smith
Journal:  BMJ       Date:  2001-01-27

Review 2.  Health sector regulation in Thailand: recent progress and the future agenda.

Authors:  Yot Teerawattananon; Viroj Tangcharoensathien; Sripen Tantivess; Anne Mills
Journal:  Health Policy       Date:  2003-03       Impact factor: 2.980

Review 3.  What is next for pharmacoeconomics and outcomes research in Asia?

Authors:  Jim Doherty; Isao Kamae; Kenneth K C Lee; Hong Li; Shu-Chun Li; Gordon G Liu; Yen-Huei Tarn; Bong-min Yang
Journal:  Value Health       Date:  2004 Mar-Apr       Impact factor: 5.725

4.  Strategies to enhance the use of health systems research for health sector reform.

Authors:  R Sauerborn; S Nitayarumphong; A Gerhardus
Journal:  Trop Med Int Health       Date:  1999-12       Impact factor: 2.622

5.  Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation.

Authors:  Cynthia P Iglesias; Michael F Drummond; Joan Rovira
Journal:  Int J Technol Assess Health Care       Date:  2005       Impact factor: 2.188

6.  A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers?

Authors:  Yot Teerawattananon; Steve Russell; Miranda Mugford
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Health technology assessment in Canada: diversity and evolution.

Authors:  David M Hailey
Journal:  Med J Aust       Date:  2007-09-03       Impact factor: 7.738

8.  The need for guidelines and the use of economic evidence in decision-making in Thailand: lessons learnt from the development of the national list of essential drugs.

Authors:  Suwit Wibulpolprasert
Journal:  J Med Assoc Thai       Date:  2008-06

9.  Policy making and roles of health technology assessment.

Authors:  Sripen Tantivess
Journal:  J Med Assoc Thai       Date:  2008-06

10.  Making sensible rationing: the use of economic evidence and the need for methodological standards.

Authors:  Viroj Tangcharoensathien; Pirom Kamolratanakul
Journal:  J Med Assoc Thai       Date:  2008-06
View more
  20 in total

1.  Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan.

Authors:  Isao Kamae
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  A Clinical Support System Based on Quality of Life Estimation.

Authors:  Brígida Mónica Faria; Joaquim Gonçalves; Luis Paulo Reis; Álvaro Rocha
Journal:  J Med Syst       Date:  2015-08-16       Impact factor: 4.460

Review 3.  How contexts and issues influence the use of policy-relevant research syntheses: a critical interpretive synthesis.

Authors:  Kaelan A Moat; John N Lavis; Julia Abelson
Journal:  Milbank Q       Date:  2013-09       Impact factor: 4.911

4.  Developing nations special issue.

Authors:  Mendel E Singer
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Is there a role for pharmacoeconomics in developing countries?

Authors:  Román Pérez Velasco; Yot Teerawattananon
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981

6.  Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets.

Authors:  Anke-Peggy Holtorf; Diana Brixner; Brandon Bellows; Abdulkadir Keskinaslan; Joseph Dye; Gary Oderda
Journal:  Am Health Drug Benefits       Date:  2012-11

7.  Incorporating cost-effectiveness data in a fair process for priority setting efforts Comment on "Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden".

Authors:  Sitaporn Youngkong
Journal:  Int J Health Policy Manag       Date:  2015-04-11

8.  Health technology assessment and its role in the future development of the Indian healthcare sector.

Authors:  Bastian Hass; Jayne Pooley; Martin Feuring; Viraj Suvarna; Adrian E Harrington
Journal:  Perspect Clin Res       Date:  2012-04

Review 9.  Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.

Authors:  András Inotai; Márta Pékli; Gabriella Jóna; Orsolya Nagy; Edit Remák; Zoltán Kaló
Journal:  BMC Health Serv Res       Date:  2012-09-21       Impact factor: 2.655

10.  The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package.

Authors:  Thunyarat Anothaisintawee; Pattara Leelahavarong; Tanapat Ratanapakorn; Yot Teerawattananon
Journal:  Clinicoecon Outcomes Res       Date:  2012-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.